The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
Open Access
- 1 January 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 8 (1), 160
- https://doi.org/10.1186/1750-1172-8-160
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- The SF-36 and SGRQ: Validity and first look at minimum important differences in IPFRespiratory Medicine, 2010
- Effects of scoliosis on respiratory muscle strength in patients with neuromuscular disordersThe Spine Journal, 2009
- The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophyMuscle & Nerve, 2009
- Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trialZeitschrift für Neurologie, 2009
- A novel mutation of the GAA gene in a Finnish late‐onset pompe disease patient: Clinical phenotype and follow‐up with enzyme replacement therapyMuscle & Nerve, 2009
- Relationships between motor impairments and activity limitations in patients with neuromuscular disordersJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Rate of disease progression during long-term follow-up of patients with late-onset Pompe diseaseNeuromuscular Disorders, 2009
- Glycogen storage disease type II (Pompe disease) – influence of enzyme replacement therapy in adultsEuropean Journal of Neurology, 2009
- Clinical features of late‐onset Pompe disease: A prospective cohort studyMuscle & Nerve, 2008
- Outcome measures in the lungRheumatology, 2008